Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities
Strategic addition strengthens Juvenescence's AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala)
Acquisition follows $76m Series B-1 financing first-close led by M42 in May 2025
Ramsey, Isle of Man, 5 June 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence's artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025.
Ro5's platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The Company's AI Chemistry Platform incorporates state-of-the art machine learning model and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation.
The acquisition of Ro5 follows Juvenescence's recent announcement of a $76 million first-close of its Series B-1 financing round led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated in the third quarter of 2025. Proceeds will support clinical milestones and AI-driven development across Juvenescence's portfolio of therapeutics targeting age-related diseases.
The integration of Ro5's AI drug discovery platform and expert team into Juvenescence will accelerate the identification and development of AI-enabled therapeutics, reinforcing the company's growing pipeline in cognition, cardio-metabolism, immunity, and cellular repair.Dr Richard Marshall CBE, CEO of Juvenescence, said: 'We are delighted to welcome the Ro5 team and the Company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.'
Charles Dazler Knuff, CEO of Ro5, added: 'The Ro5 team are thrilled to be joining the world class drug development team at Juvenescence. Embedding our AI-driven drug discovery capabilities into Juvenescence's operations will accelerate their ability to advance next-generation therapeutics. Together with our partners at M42 we are also laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.'
About Juvenescence Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases.
It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales.
Powered by an unrivaled drug development team, Juvenescence leverages cutting-edge AI tools to unlock successful therapeutics. The company's diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine.
For more information, visit: www.JuvLabs.com
About Ro5
In the race to save and improve lives, Ro5 accelerates drug discovery, development, repurposing, and clinical trials. We enrich our client's data with our proprietary database, then use machine learning platforms to reduce discovery time from years to months, increase accuracy, and, at every point, lower costs. Our proprietary state-of-the-art neural network architectures learn the complex relationships between a molecule's basic physicochemical properties and its more general pharmacological characteristics and are real and effective.
Investor Relations Contact: juvenescenceir@juvlabs.com
Media contact:
ICR Healthcare
Jessica Hodgson / Chris Welsh
Juvenescence@icrhealthcare.com
Forward-Looking Statements
Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Exclusive-US suspends licenses to ship nuclear plant parts to China, sources say
By Karen Freifeld and Fanny Potkin (Reuters) -The U.S. in recent days suspended licenses for nuclear equipment suppliers to sell to China's power plants, according to four people familiar with the matter, as the two countries engage in a damaging trade war. The suspensions were issued by the U.S. Department of Commerce, the people said, and affect export licenses for parts and equipment used with nuclear power plants. Nuclear equipment suppliers are among a wide range of companies whose sales have been restricted over the past two weeks as the U.S.-China trade war shifted from negotiating tariffs to throttling each other's supply chains. It is unclear whether a Thursday call between U.S. President Donald Trump and Chinese President Xi Jinping would affect the suspensions. The U.S. and China agreed on May 12 to roll back triple digit, tit-for-tat tariffs for 90 days, but the truce between the two biggest economies quickly went south, with the U.S. claiming China reneged on terms related to rare earth elements, and China accusing the U.S. of "abusing export control measures" by warning that using Huawei Ascend AI chips anywhere in the world violated U.S. export controls. After Thursday's call, further talks on key issues were expected. The U.S. Department of Commerce did not respond to a request for comment on the nuclear equipment restrictions. On May 28, a spokesperson said the department was reviewing exports of strategic significance to China. "In some cases, Commerce has suspended existing export licenses or imposed additional license requirements while the review is pending," the spokesperson said in a statement. The Chinese Embassy in Washington did not immediately respond to a request for comment. U.S. nuclear equipment suppliers include Westinghouse and Emerson. Westinghouse, whose technology is used in over 400 nuclear reactors around the world, and Emerson, which provides measurement and other tools for the nuclear industry, did not respond to requests for comment. The suspensions affect business worth hundreds of millions of dollars, two of the sources said. They also coincide with Chinese restrictions on critical metals threatening supply chains for manufacturers worldwide, especially America's Big Three automakers. Reuters could not determine whether the new restrictions were tied to the trade war, or if and how quickly they might be reinstated. Department of Commerce export licenses typically run for four years and include authorized quantities and values. But many new restrictions on exports to China have been imposed in the last two weeks, according to sources, and include license requirements for a hydraulic fluids supplier for sales to China. Other license suspensions went to GE Aerospace for jet engines for China's COMAC aircraft, sources said. The U.S. also now requires licenses to ship ethane to China, as Reuters reported first last week. Houston-based Enterprise Product Partners said Wednesday that its emergency requests to complete three proposed cargoes of ethane to China, totaling some 2.2 million barrels, had not been granted. Enterprise said a May 23 requirement for a license to sell butane to China, in addition to the ethane, was subsequently withdrawn. Dallas-based Energy Transfer said it was notified on Tuesday about the new ethane licensing requirement, and planned to apply and file for an emergency authorization. Other sectors that have been hit with new restrictions include companies that sell electronic design automation software such as Cadence Design Systems. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
‘Cable cowboy' to put 30,000 EV chargers on Britain's roads
'Cable cowboy' John Malone is bankrolling a deal to put 30,000 new electric vehicle (EV) chargers on Britain's roads. Liberty Global, which is controlled by the US billionaire, is spearheading a £300m investment in charge point operator Believ that will improve public access to chargers across the UK. The deal will deliver a major boost to the expansion of the UK's public charging network, which is a crucial factor in persuading drivers to switch to EVs. The Government has set a target of reaching 300,000 public charge points by the end of the decade, but drivers currently only have access to around 80,000. Believ will partner with both public and private sector organisations to roll out the new chargers where they are needed most. Most of the investment will go towards on-street, residential locations to help drivers without off-street parking transition to EVs. Funding will also be allocated to rapid and ultra-rapid charging hubs, as well as rural locations. Denver-based Liberty Global is controlled by Mr Malone, a Trump-supporting billionaire who is one of the largest individual landowners in the US. The 84-year-old holds a number of US media and entertainment assets, including Formula One. He is also a shareholder and board member at Warner Bros Discovery. An aggressive dealmaker, Mr Malone's holdings in paid TV and telecoms have earned him the nickname the 'cable cowboy'. Expansion into EV charging represents a new market for Mr Malone but builds on his other business interests. Believ partners with Virgin Media O2, which is also jointly owned by Liberty Global, to deploy its charging infrastructure. Guy Bartlett, the chief executive of Believ, said the funding 'recognises the scale of investment required and the urgency of the need'. He added: 'Confidence in EVs will continue to grow as drivers see more infrastructure going into the ground.' Figures published this week by the Society of Motor Manufacturers and Traders (SMMT) showed that one in five new cars sold in Britain were battery-powered. Sales have been boosted by heavy discounting, but a rise in EV chargers is also starting to pay off. A record of nearly 3,000 charging devices were added to Britain's roads in April, equivalent to one every 29 minutes. Lilian Greenwood, the roads minister, said: 'We're working hard to ensure all drivers can charge easily and conveniently – no matter where they are. 'Believ's investment is a brilliant vote of confidence in the transition to electric and another fantastic example of Government and industry working together to roll out tens of thousands of charge points across the country.' In addition to private funding, the Government has pledged £2.3bn to support the switch to EVs, with a £200m budget to help expand public charging and a dedicated £381m fund for local authorities. Zouk Capital, the private equity firm that jointly owns Believ alongside Liberty Global, is also contributing to the funding, alongside banks Santander, ABN Amro, NatWest and MUFG. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
19 minutes ago
- Yahoo
Why PTC Inc. (PTC) is a Top Value Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks. Boston, MA-based PTC Inc is a software provider offering a range of cutting-edge digital technologies that collectively revolutionize the engineering, production, and maintenance of tangible goods. Founded in 1985, the company was formerly known as Parametric Technology Corporation and changed its name to PTC Inc in January 2013. PTC sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of A. Compared to the Computer - Software industry's P/E of 27.8X, shares of PTC Inc. are trading at a forward P/E of 27.8X. PTC also has a PEG Ratio of 1.8, a Price/Cash Flow ratio of 34.6X, and a Price/Sales ratio of 8.6X. Many value investors pay close attention to a company's earnings as well. For PTC, six analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.25 to $6.03 per share for 2025. Per share PTC boasts an average earnings surprise of 14.6%. Investors should take the time to consider PTC for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PTC Inc. (PTC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
